公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
公司地址 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
電話號碼 +1 724 514-1800
傳真號碼 --
公司網頁 https://www.viatris.com
員工數量 30000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Corinne Le Goff, Pharm.D. Chief Commercial Officer 美元 899.33K 02/04/2026
Mr. Matthew Maletta Chief Legal Officer -- 02/04/2026
Mr. Matthew J. Maletta Chief Legal Officer -- 03/02/2026
Mr. Paul B. Campbell Chief Accounting Officer and and Corporate Controller -- 02/04/2026
Mr. Scott A. Smith Director and Chief Executive Officer 美元 1.45M 02/04/2026
Ms. Theodora Mistras Chief Financial Officer 美元 849.33K 02/04/2026
Mr. Andrew Enrietti Chief Administrative and Transformation Officer 美元 684.90K 02/04/2026
 
董事會成員
董事會 職務 更新日期
Mr. Frank D’Amelio Independent Director 02/04/2026
Dr. Michael Severino, M.D. Independent Director 02/04/2026
Mr. James M. Kilts Independent Director 02/04/2026
Mr. Leo Groothuis Independent Director 02/04/2026
Mr. Wyllie Don Cornwell Independent Director 02/04/2026
Mr. Mark W. Parrish Vice Chairman of the Board 02/04/2026
Ms. Melina E. Higgins Chairman of the Board 02/04/2026
Mr. David S. Simmons Independent Director 02/04/2026
Ms. JoEllen Lyons Dillon Independent Director 02/04/2026
Dr. Rogerio Vivaldi Coelho, M.B.A.,M.D. Independent Director 02/04/2026
Mr. Richard A. Mark, C.P.A. Independent Director 02/04/2026
Ms. Elisha W. Finney Independent Director 02/04/2026
Mr. Scott A. Smith Director and Chief Executive Officer 02/04/2026
 
所屬ETF (更新日期: 02/05/2026 02:25)
代號 名稱 佔比% 持有日期
JDIVJPMorgan US Dividend ETF0.001%31/08/2022
LYLDCambria LargeCap Shareholder Yield ETF0.001%29/04/2026
GOFGuggenheim Strategic Opp Fund0.001%30/11/2025
SPXTProShares S&P 500® ex-Technology0.001%29/04/2026
SFYSoFi Select 500 ETF0.001%29/04/2026
URSPProShares Ultra S&P 500 Equal Weight0.001%28/02/2026
PBPInvesco S&P 500 BuyWrite ETF0.001%29/04/2026
AFMCFirst Trust Active Factor Mid Cap ETF0.001%29/04/2026
SQSSapient Quality Select ETF0.001%17/04/2026
STXVStrive 1000 Value ETF0.0004%29/04/2026
DFVEDoubleLine Fortune 500 Equal Weight ETF0.0004%29/04/2026
HCMTDirexion HCM Tactical EnhU.S.EqStratETF0.0004%29/04/2026
SPUUDirexion Daily S&P 500® Bull 2X ETF0.0003%29/04/2026
XMAGDefiance Large Cap ex-Mag 7 ETF0.0003%29/04/2026
ABCSAlpha Blue Capital US Sm-Md Cp Dyn ETF0.0003%29/04/2026
MEDXHorizon Kinetics Medical ETF0.0003%29/04/2026
AAUAAlpha Architect US Equity 3 ETF0.0002%10/04/2026
SPXNProShares S&P 500® ex-Financials0.0001%29/04/2026
SPXEProShares S&P 500® ex-Energy0.0001%29/04/2026
AVTMAvantis Total Equity Markets ETF0.0001%29/04/2026
  1    2    3    4    5    6    7    8   9    10    11    12    13    14  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.